Anjarium Biosciences

Anjarium Biosciences is a pre-clinical biotechnology company focused on advancing its bioinspired therapeutic delivery platform to develop a new generation of targeted medicines for a broad range of severe diseases.

Founded in 2016, Anjarium Biosciences AG is a privately owned biotechnology company aiming to mimic native intercellular communication pathways in order to generate a novel class of bioinspired nanomedicines that can precisely, efficiently and safely deliver an array of therapeutics to several disease targets throughout the body.

Our dedicated team is advancing its proprietary platform to accelerate the development of extracellular vesicle-based therapies. Anjarium’s Hybridosome™ technology creates unmatched competitive advantages in the realm of engineering extracellular vesicles (including exosomes) to act as smart carriers and to maximize the therapeutic potential of naturally occurring vesicles.